3 results
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
To investigate if VRcbt is more (cost-)effective than standard CBT for treatment of paranoid delusions and improving daily life social functioning of patients with schizophrenia and related psychotic disorders.
The objective of this study is to pilot this novel VR treatment for social interaction difficulties (VR-SOAP) in preparation of a subsequent randomized controlled trial (RCT). The aim of the study is threefold: 1) to investigate the feasibility and…